MOUD Buprenorphine Subli denied as not medically necessary by Centene?

Mirrors state Medicaid PDLs. Most state Medicaid programs (post-2023 X-waiver removal) allow PCP prescribing without specialist gatekeeping.

MATA Act 2022 / DATA 2000 X-waiver removal — any DEA-registered prescriber may prescribe buprenorphine. ASAM NPG OUD 2020 first-line. SAMHSA TIP 63 supports doses >24 mg for fentanyl-era patients. EPSDT for under-21.

## Why Centene Issued This Denial

Centene's medical-necessity denial for sublingual buprenorphine (MOUD) means a clinical reviewer determined — based on the information submitted — that the documentation did not satisfy Centene's criteria for medical necessity. This is one of the most common denial types for MOUD and is frequently the result of incomplete documentation rather than a patient who does not genuinely qualify.

Medical-necessity denials for MOUD are also subject to heightened scrutiny under the Mental Health Parity and Addiction Equity Act (MHPAEA). Centene must be able to show that the medical-necessity criteria it applies to buprenorphine MOUD are no more restrictive than those applied to analogous treatments for other chronic medical conditions. If they cannot, the denial may be challengeable on parity grounds independently of the clinical documentation.

## Why This Denial Is Appealable

Medical-necessity denials are overturned regularly when a well-structured appeal closes the documentation gap identified in the denial. The key is to obtain Centene's exact coverage criteria, then build an appeal that addresses each criterion with a specific, dated chart entry.

## Federal Appeal Framework

• Internal appeal (Level 1): File within the deadline stated in your denial letter. Centene must respond within 30 days (standard) or 72 hours (urgent/expedited).
• External review (ACA §2719 / ERISA §503): Available after the internal appeal is exhausted — generally within four months of the final internal denial. An IRO reviews whether Centene's medical-necessity determination was consistent with its own criteria and with generally accepted clinical standards.
• Expedited review: If delaying the medication would seriously jeopardize health — a clinically strong argument in MOUD cases — request expedited processing.

## Concrete Appeal Steps

1. Request Centene's clinical coverage policy for buprenorphine MOUD — this contains the exact medical-necessity criteria used to evaluate your claim. 2. Review the denial letter to identify which specific criteria Centene found unsatisfied. 3. Work with the prescriber to prepare a detailed medical-necessity letter that addresses each unsatisfied criterion by name, citing specific chart documentation with dates. 4. Compile supporting records: diagnosis confirmation, prior treatment history, clinical severity documentation, and any standardized assessments used in the patient's care. 5. If applicable, include a MHPAEA parity argument. 6. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Centene's clinical coverage policy for buprenorphine MOUD
• Prescriber's medical-necessity letter addressing each coverage criterion
• Confirmed opioid use disorder diagnosis with dates
• Prior treatment history — what was tried, when, with what outcome
• Clinical severity documentation from the chart (assessment notes, progress notes)
• FDA prescribing label for the specific sublingual buprenorphine product

## Criteria-Mapping Structure

For every criterion in Centene's policy, document the chart evidence:

| Centene Medical-Necessity Criterion | Chart Evidence | |---|---| | Confirmed OUD diagnosis | Dated chart note + ICD-10 code | | Prescriber qualified to prescribe buprenorphine for OUD | Prescriber credentials on file | | Treatment consistent with FDA-approved indication | FDA label + prescriber treatment rationale | | Prior treatment history documented (if required) | List of prior treatments with dates/outcomes | | Clinical severity supports treatment | Assessment notes, progress notes |